STM JOURNALS

International Journal of
Antibiotics

ISSN: 2584-2986
Volume 2, Issue 1, 2025
January–June
DOI (Journal): 10.37591/IJAB

https://journals.stmjournals.com/ijab

Review IJAB

Antimicrobial Peptides and Bacteriophages as Next-Generation Alternatives to Conventional Antibiotics

Sudipta Roy*

Abstract

The growing threat of antibiotic-resistant bacteria has underscored the urgent need for innovative alternatives to conventional antibiotics. Antimicrobial peptides (AMPs) and bacteriophages are gaining recognition as next-generation therapeutics due to their distinct mechanisms of action and ability to target resistant pathogens effectively. AMPs, which can be natural or synthetic, disrupt microbial membranes and offer broad-spectrum antimicrobial activity with a reduced likelihood of resistance development. Bacteriophages, as bacteria-specific viruses, provide precise targeting of pathogens while preserving beneficial microbiota and possess the ability to co-evolve with bacterial resistance mechanisms. These approaches hold significant promise for treating challenging infections, including those involving biofilms and multidrug-resistant bacteria. Furthermore, phage therapy can complement traditional antibiotics, potentially reducing the overuse of antibiotics and mitigating the rise of resistance. Additionally, phage cocktails, which combine multiple bacteriophages, enhance the effectiveness and reduce the likelihood of bacterial resistance development, offering a versatile and adaptive therapeutic strategy. However, obstacles, such as ensuring stability, efficient delivery, and navigating regulatory requirements persist. Advances in formulation technologies, including encapsulation and nanotechnology, are paving the way for improved efficacy and clinical implementation. This abstract highlights AMPs and bacteriophages as innovative and sustainable strategies to combat the escalating crisis of antibiotic resistance.

Keywords: Antimicrobial peptides, antimicrobial resistance, bacteriophages, biofilms, novel formulations for antimicrobial peptides

INTRODUCTION

Once a potent treatment for bacterial infections, bacteriophage therapy is currently being investigated for its potential to treat illnesses that are resistant to antibiotics. Coding sequences for 1018 or mCherry have been inserted into the genome of the T7Select phage by researchers to create a phage-driven antimicrobial peptide expression system. The 1018 T7 phage is more effective than the unmodified T7Select phage, and the system has demonstrated quick impacts on E. coli cells. Before these genetically altered phages may be used in vivo, more testing and refinement are required [1]. Antimicrobial peptides (AMPs) are endogenous compounds with broad antibiotic activity and anti-inflammatory properties. They have been used to develop new antimicrobial drugs to address antibiotic resistance [2]. Antibiotics are essential tools for treating bacterial infections and have significantly contributed to increased life expectancy. However, the rapid spread of antimicrobial resistance (AMR) poses a critical threat. The first antibiotic-resistant strains were noted as early as World War II, and since then, resistance has led to severe infections, particularly

***Author for Correspondence**
Sudipta Roy
E-mail: sudiptaroy89@gmail.com

Associate Professor, Bengal College of Pharmaceutical Technology, Dub Rajpur, Birbhum, West Bengal, India

Received Date: November 25, 2024
Accepted Date: December 03, 2024
Published Date: December 07, 2024

Citation: Sudipta Roy. Antimicrobial Peptides and Bacteriophages as Next-Generation Alternatives to Conventional Antibiotics. International Journal of Antibiotics. 2025; 2(1): 9–27p.

among hospitalized and immunocompromised patients. In the United States alone, antibiotic-resistant bacteria infect at least two million people annually, causing approximately 23,000 deaths. Several factors contribute to the rise in AMR, including the overuse and misuse of antibiotics, lack of public awareness and education, insufficient regulatory measures, and inadequate water and sanitation infrastructure. Resistance among Gram-negative bacilli is especially concerning in Asia, where studies show high resistance rates against commonly used antibiotics in seven countries. To address this crisis, researchers are exploring alternative approaches to "reset the clock" on bacterial resistance in specific pathogens. Emerging strategies for developing new antimicrobial agents include antimicrobial peptides, phage therapy, plant-based phytochemicals, metallo-antibiotics, lipopolysaccharide inhibitors, and efflux pump inhibitors. These novel therapies hold promise for combating resistance and sustaining effective infection control [3]. Antibiotic-resistant ESKAPE infections, such as Enterococcus fecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, were responsible for more than a million deaths globally in 2019. The WHO also notes that Helicobacter and Campylobacter that are resistant to antibiotics pose a major risk to human health. Alternative approaches are desperately needed to fight antimicrobial resistance (AMR), particularly in difficult-to-treat bacterial communities that form biofilms, as new antibiotics are becoming less common. Notwithstanding their wide-ranging effects, AMPs have drawbacks, such as instability and possible toxicity. Their efficacy as medication candidates may be increased by creating AMP mimics. AMR may be effectively addressed by combining AMPs with a one-health strategy, new AMP synthesis techniques, and phage therapy developments [4]. Antimicrobial peptides (AMPs) are short peptides, typically composed of 10-60 amino acid residues, with a positive charge ranging from +2 to +9. They are both hydrophobic and amphipathic in nature. AMPs are classified into several categories, including α-helical, β-sheet, linear extended, non-α/β, α/β, loop, or β-hairpin structures, with α-helical and β-sheet peptides being the most common. The rise of antimicrobial resistance (AMR) is often referred to as the "silent pandemic," fueled by the overuse of antibiotics in agriculture and animal husbandry. By 2050, it is estimated that AMR will cause 10 million deaths annually, surpassing deaths from cancer and diabetes combined. To combat this, alternative treatments, such as phage therapy, nanomaterials, nanoparticles, and AMPs are being researched to address both antibiotic resistance and biofilm-related infections. Despite their broad-spectrum efficacy against bacteria, fungi, parasites, and viruses, some mechanisms of AMPs are not yet fully understood. Further research is needed to assess their effectiveness and safety for clinical use [5].

MATERIALS AND METHOD

Antimicrobial resistance (AMR) has become a significant global health concern, as highlighted by health organizations around the world. To tackle this issue, emerging strategies, such as antimicrobial peptides (AMPs) and Bacteriophages therapies are being explored. These advanced methods aim to effectively target multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacterial infections while reducing dependence on conventional antibiotics.

Secondary Pathways

Antimicrobial peptides (AMPs) are small proteins with various amino acids, including synthetic and naturally produced ones. They have various biological activities, including antimicrobial, antiviral, antifungal, anti-mitogenic, antitumor, anti-inflammatory, and immune modulator properties. AMPs are a potential alternative to drugs and show therapeutic activity in both in vitro and in vivo models. Human cathelicidin peptide (LL-37) is a potent antimicrobial and anti-biofilm agent with wound-healing effects and antimicrobial activity against various human pathogens. A vital peptide antibiotic called colistin is used as a last resort to treat MDR infections, especially hospitalized patients' Gram-negative bacterial infections. Two novel colistin-derived AMPs, AA139 and SET-M33, are being developed and exhibit encouraging in vitro and in vivo therapeutic promise. AMPs' sensitivity to proteolytic digestion in body fluids affects their stability and pharmacokinetic profile. The search for new AMPs, particularly selectively targeted AMPs (STAMPs), continues due to their increased sensitivity to specific pathogens and bactericidal capacity without direct effects on the microbiota. STAMP technology requires two

functionally independent peptide domains integrated through a small linker, enhancing local concentration and bactericidal efficiency. Recent promising STEMs have been developed against Streptococcus mutans, Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, and clinical isolates. Combinations of cationic amphipathic peptides (AMPs) with antibiotics have shown synergistic effects in treating bacterial infections. These combinations disrupt the outer membrane, enhancing antimicrobial effects and reducing doses. Recent studies have shown synergistic activity between AMPs and antibiotics, such as melittin and LL-37. Synthetic peptides inspired by human cationic peptides have also shown antibacterial and anti-biofilm activity. Synergistic combinations of peptides, polymyxin B, erythromycin, tetracycline, and novel variants of indolicidin have also been found. This presents an opportunity to design treatment strategies based on synergistic interactions [6].

Phage therapy, a method of treating bacterial infections, has been around since the early 20th century. The first phage activity was reported in 1896 by Ernest Hankin, who discovered that water from rivers Ganges and Yamuna in India had antibacterial activity against Vibrio cholerae. French microbiologist Felix d'Herelle identified bacterium eaters (phages) that specifically parasitized bacteria, leading to the development of phage therapy. However, due to the development of antibiotics, phage therapy was largely abandoned in the Western world. Recently, phages have re-emerged as an alternative to antibiotics in combating multi-drug-resistant bacteria. Phages, or bacteriophages, are lytic viruses that infect bacterial species, showing bactericidal effects against both Gram-positive and Gram-negative bacteria. Phage therapy and its endolysins offer the possibility of applying more specific antibacterial treatments and a potential solution to antibiotic resistance [7].

Formulation of Antimicrobial Peptides

Antibiotic-resistant infections are a global health issue affecting millions of people annually, with over two million in the US alone. These infections are linked to over 100,000 deaths and pose a threat to all age groups, particularly infants, young children, older adults, and those with compromised immune systems. Reducing infections could lead to significant savings and improved patient outcomes.

As a result, there is an urgent need to develop innovative antimicrobial strategies to combat resistance, lower mortality rates, minimize healthcare costs, and prevent widespread outbreaks.

AmPs (antibiotics) are attractive due to their non-specific nature, broad spectrum, and rapid bactericidal action. Traditional antibiotics have high manufacturing costs, short in-vivo lifetimes, and lack of understanding of systemic toxicity. Advancements in solid phase chemical synthesis reduce costs and improve drug delivery methods.

AmPs are peptides that enter and kill bacteria, influencing protein production, DNA, and RNA. They prevent structural elements and enzymatic activity. Bacteria are less resistant due to non-specific absorption and membrane modifications, with few resistant strains decreasing viability.

Antimicrobial peptides (AMPs) are naturally occurring peptides in living things, enhancing the immune system's ability to target intracellular targets and bacterial membranes.

Recent developments in synthetic AMP engineering, delivery methods, and combination treatments have led to the development of AmPs, short peptides with significant antibacterial properties. These peptides serve as a defense against invasive infections and contribute to the innate immune system's recruitment. They have four structural classes and can cause membrane permeation and cell lysis.

Extraction of Antimicrobial Peptides (AMPs) from Human Skin Secretions, Saliva, and Neutrophils

Antimicrobial peptides, found in skin secretions, saliva, and neutrophils, are being explored for their potential in developing advanced antimicrobial treatments.

Extraction of AMPs from Skin Secretions

The skin functions as both a physical and biochemical shield, producing AMPs like cathelicidins (e.g., LL-37) and defensins to combat microbial invaders.

Skin Secretion Collection

- To utilize non-invasive techniques, such as tape stripping or washing the skin with sterile phosphate-buffered saline (PBS).
- Alternatively, collecting sweat through mild exercise or sauna sessions and absorbing it using sterile pads.

Sample Processing

- To centrifuge the collected material to eliminate particulates.
- To filter the supernatant using a 0.22 μm membrane to remove microbial contaminants.

Peptide Extraction

- To use acid-based methods with acetic acid or trifluoroacetic acid (TFA) to extract peptides.
- To employ solid-phase extraction (e.g., C18 reverse-phase columns) to concentrate the peptides.
- Purification and Analysis:
- To isolate peptides using high-performance liquid chromatography (HPLC).
- To characterize them via mass spectrometry (MS) or peptide sequencing techniques.

Extraction of AMPs from Saliva

- Saliva, a natural reservoir of AMPs, such as histatins, defensins, and cathelicidins, plays a crucial role in controlling microbial populations in the oral cavity.
- Saliva Collection:
- Collecting unstimulated saliva in sterile tubes or induce secretion using paraffin wax.
- Removing debris by centrifugation to obtain a clear supernatant.

Peptide Precipitation

- Precipitating proteins and peptides by adding cold ethanol or acetone.
- Removing larger proteins using ultrafiltration membranes (e.g., 10 kDa molecular weight cutoff).

Peptide Purification

- Processing the filtrate on a C18 reverse-phase extraction column.
- Eluting peptides using an acetonitrile-water gradient containing TFA.

Characterization

Analyzing peptides with techniques, such as electrophoresis, HPLC, or MS for identification and quantification.

Extraction of AMPs from Neutrophils

Neutrophils are a primary source of AMPs, including defensins (HNP1-3) and cathelicidins (e.g., LL-37), stored in granules and released during immune responses.

Neutrophil Isolation

- Collecting blood samples treated with anticoagulants like EDTA or heparin.
- Separating neutrophils using density gradient centrifugation (e.g., Ficoll-Paque or Percoll).

Granule Extraction

- Disrupting neutrophils through hypotonic lysis or nitrogen cavitation to release granules.
- Isolating granules using differential centrifugation techniques.

Peptide Recovery
- Solubilizing peptides from granules using acidic buffers (e.g., 0.01% acetic acid).
- Centrifuging to remove insoluble debris.

Purification and Characterization
- Purifying peptides with methods like gel filtration, ion-exchange chromatography, or HPLC.
- Verifying peptide identity through MS or peptide sequencing.

Challenges in AMP Extraction
- *Low Yield:* AMPs are often present in minute quantities, necessitating highly sensitive extraction methods.
- *Contamination Risks:* The presence of other proteins or impurities can hinder purity.
- *Proteolytic Degradation:* Proteases can degrade peptides during handling, reducing recovery efficiency.

Applications of Extracted AMPs
- *Therapeutics:* Development of treatments for infections caused by antibiotic-resistant pathogens.
- *Diagnostics:* Using as biomarkers for detecting infections or monitoring immune responses.
- *Research:* Exploring their roles in immunity and interactions with pathogens.

Optimizing these extraction methods can enhance the yield and functional application of AMPs, paving the way for their use in therapeutic and diagnostic innovations.

Antimicrobial peptides (AMPs) are compounds produced by various species that provide a host's natural defense against infections. These peptides have antiviral, antiparasitic, antineoplastic, and immunomodulatory properties. They can be found in various molecular architectures, including lipopeptides, macrocyclic, cyclic, linear, tiny proteins, and self-assembling peptides. Some peptides, like gramicidin A and alamethicin, are less selective against microorganisms than against mammalian cells. Defensins in mammals protect against infection by inhibiting AMP activation, increasing wound colonization, and reducing Salmonella virulence. AMPs have clinical potential beyond antibiotic-resistant infections, stimulating the host's immune response and aiding in pathogen clearance. Cell-penetrating peptides have therapeutic potential against cancer, but their therapeutic potential as anti-infective agents have not been realized. Class-I bacteriocins contain methyl-lanthionine and other non-standard residues, while class II bacteriocins display activity against foodborne pathogens and have anti-cancer and antiviral activity. Cyclic NRAMP lipopeptides like Daptomycin (Dpt) are already marketed or in clinical trials. Streptogramins produce cyclic hexadepsipeptides with moderate bacteriostatic activity and bactericidal effects. AMPs have been actively sought out due to their stability, low toxicity, and therapeutic index.

CsA in PEG-PLGA Nanoparticles (NPs)

Recently, CsA in PEG-PLGA nanoparticles (NPs) with good colloidal stability were obtained. These NPs, stabilized by bovine serum albumin, released 55.6% of CsA on day 1 and showed potential for maintaining therapeutic concentrations in vivo. The formulation efficiently suppressed T-cell proliferation and inflammatory cytokine production.
- *Drug:* Cyclosporine A (CsA), a hydrophobic immunosuppressant.
- *Polymer:* Poly (ethylene glycol)-block-poly (lactic-co-glycolic acid) (PEG-PLGA), an amphiphilic block copolymer used for nanoparticle formulation.
- *Solvents:* Organic solvents, such as dichloromethane (DCM), acetone, or ethanol to dissolve CsA and PEG-PLGA.
- *Aqueous Phase Stabilizer:* Polyvinyl alcohol (PVA) or surfactants like Pluronic F68 to stabilize nanoparticles.
- *Buffers:* Phosphate-buffered saline (PBS) or similar solutions for washing and suspending nanoparticles.

Preparation of PEG-PLGA Nanoparticles

Depending on CsA's solubility, either a single emulsion (oil-in-water) or double emulsion (water-in-oil-in-water) method is employed.

- *Single Emulsion Solvent Evaporation Method (suitable for hydrophobic drugs like CsA):* Dissolving PEG-PLGA and CsA in an organic solvent (e.g., DCM or acetone).

Removing the organic solvent through evaporation under reduced pressure or continuous stirring to form nanoparticles encapsulating CsA.

Double Emulsion Method (Used if a Hydrophilic Environment Is Required for CsA)

- Dissolving CsA in a small volume of water or a suitable co-solvent to form a primary emulsion.
- Dispersing the primary emulsion into an organic phase containing PEG-PLGA.
- Proceeding with homogenization and solvent removal as described for the single emulsion method.

Stabilization and Purification of Nanoparticles

- Stirring the emulsion thoroughly to ensure complete removal of residual solvents.
- Separating nanoparticles using centrifugation or filtration techniques.
- Washing nanoparticles with water or PBS to remove unencapsulated CsA and excess stabilizers.
- Characterization of CsA-Loaded PEG-PLGA Nanoparticles.

Particle Size and Zeta Potential

Measuring using dynamic light scattering (DLS) or a zeta sizer to determine size distribution and surface charge.

Drug Encapsulation Efficiency (EE)

Quantifying encapsulated CsA using high-performance liquid chromatography (HPLC) or UV-Vis spectroscopy.

Drug Loading (DL)

Calculating the drug-to-polymer ratio to evaluate loading efficiency.

Morphology

Confirming nanoparticle structure using scanning electron microscopy (SEM) or transmission electron microscopy (TEM).

Release Profile

Conducting in vitro drug release studies in a buffer solution (e.g., PBS with Tween 80) and measure CsA release over time using HPLC.

Optimization Parameters

- Polymer Concentration: Impacting nanoparticle size and drug encapsulation efficiency.
- Solvent Selection: Affecting the solubility of CsA and overall nanoparticle stability.
- Surfactant Concentration: Influencing particle size and preventing aggregation during emulsification.
- Drug-to-Polymer Ratio: Balancing the loading capacity and encapsulation efficiency of CsA.

Liposomal Formulations

Artificial phospholipid vesicles are biocompatible, biodegradable, and nontoxic, capable of entrapping and carrying hydrophilic, hydrophobic, and amphiphilic molecules to their action sites.

The encapsulation of Amphotericin B (AmB), a hydrophobic antifungal agent, in liposomes offers a promising approach to enhance its solubility, reduce toxicity, and improve therapeutic efficacy.

Commercial formulations like *AmBisome*® highlight the advantages of liposomal AmB in clinical settings.

- *Active Drug:* Amphotericin B (AmB).
- *Phospholipids:* Examples include hydrogenated soy phosphatidylcholine (HSPC) or distearoylphosphatidylcholine (DSPC).
- *Cholesterol:* Stabilizes the lipid bilayer.
- *Anionic Lipids:* Distearoylphosphatidylglycerol (DSPG) improves drug encapsulation efficiency.
- *Solvents:* Ethanol or chloroform for dissolving lipids.
- *Aqueous Phase:* Hydration buffer, such as phosphate-buffered saline (PBS) or citrate buffer.
- *Cryoprotectants:* Sucrose or trehalose, useful for lyophilization and enhanced storage stability.

Thin Film Hydration Method

- *Lipid Dissolution:* Dissolving phospholipids, cholesterol, and DSPG in a volatile organic solvent (e.g., chloroform or a chloroform-methanol mixture).
- *Film Formation:* Using a rotary evaporator to evaporate the solvent under reduced pressure, forming a thin lipid film on the flask's interior wall.
- *Hydration:* Hydrating the lipid film with an aqueous buffer containing AmB at a temperature above the lipid's transition temperature (usually 55–65°C for DSPC or HSPC). Stir or vortex to generate multilamellar vesicles (MLVs).
- *Size Reduction:* Reducing the size of MLVs into small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs) using probe sonication or extrusion through polycarbonate membranes.

Reverse Phase Evaporation Method

- *Organic Phase Preparation:* Dissolving lipids in a suitable organic solvent, such as chloroform or ether, and mix with an aqueous AmB solution to form a water-in-oil emulsion.
- *Emulsion Evaporation:* Removing the solvent under reduced pressure to form a gel-like structure, which eventually collapses into liposomes.
- *Size Optimization:* Using homogenization or extrusion to create liposomes with a uniform size distribution.

Active Loading via pH Gradient

- Preparing empty liposomes in a low-pH buffer (e.g., citrate buffer).
- Dissolving AmB in a solvent like DMSO or ethanol and add it to the liposome suspension. Incubate at elevated temperatures to facilitate drug diffusion into the liposomes via the pH gradient.

Characterization of Liposomal AmB

- *Size and Surface Charge:* Measuring particle size and zeta potential using dynamic light scattering (DLS).
- *Encapsulation Efficiency (EE):* Quantifying AmB encapsulation using UV-Vis spectroscopy (approximately 408 nm) or HPLC after liposome lysis.
- *Morphology:* Evaluating the structural integrity and morphology using cryo-transmission electron microscopy (cryo-TEM).
- *Drug Release Profile:* Conducting in vitro release studies in physiological buffers to analyze release kinetics.
- *Stability Studies:* Assessing both physical and chemical stability during storage.

Optimization Parameters

- *Lipid Composition:* Adjusting the proportions of phospholipids, cholesterol, and DSPG to optimize encapsulation and stability.
- *Hydration Buffer:* Using citrate buffer to improve AmB solubility and enhance encapsulation efficiency.

- *Size Control:* Smaller liposomes (<200 nm) improve tissue distribution and minimize toxicity.
- *Drug-to-Lipid Ratio:* Optimizing the ratio to balance drug loading and liposome integrity.

Preparation of Bilayer Disks as Lipid-Based Carriers for Antimicrobial Peptides (AMPs)

Bilayer disks, often referred to as bicelles or nanodisks, are flat, disc-shaped lipid assemblies made of phospholipid bilayers stabilized at the edges with amphiphilic molecules. These structures are particularly suitable for delivering AMPs because they are biocompatible, shield peptides from degradation, and enable controlled release.

- *Lipids:* Phospholipids (e.g., phosphatidylcholine, phosphatidylglycerol): Form the core of the bilayer.
- *Edge Stabilizers (e.g., lyso-phospholipids, bile salts, or detergents):* Prevent aggregation and stabilize the edges.
- *AMPs:* Hydrophilic or amphiphilic peptides designed to integrate into the bilayer or interfacial zones.
- *Organic Solvents:* Solvents, such as chloroform, methanol, or ethanol to dissolve lipids.
- *Buffers:* Aqueous solutions like phosphate-buffered saline (PBS) or Tris buffer for lipid rehydration.
- *Optional Stabilizers:* Polyethylene glycol (PEG)-lipids or surfactants for enhanced structural stability and extended circulation in the body.

Lipid Film Preparation

- *Lipid Dissolution:* Dissolving phospholipids and edge stabilizers in a mixture of organic solvents (e.g., chloroform and methanol).
- *Thin Film Formation:* Removing the solvent using a rotary evaporator under reduced pressure, creating a thin, uniform lipid layer on the wall of a round-bottom flask.
- *Solvent Removal:* Applying vacuum for 1–2 hours to ensure all residual solvents are eliminated.

Rehydration and Disk Formation

- *Film Hydration:* Adding an aqueous buffer (e.g., PBS or Tris) to the lipid film, incorporating the desired concentration of AMP. Stir or vortex to form a multilamellar suspension.
- *Sonication or Extrusion:* Using probe sonication or pass the suspension through an extrusion membrane to break vesicles into smaller, disk-shaped structures.
- *Edge Stabilization:* Incorporating edge stabilizers, such as bile salts or lyso-phospholipids, to fine-tune the disk size and shape.

Incorporation of AMPs

- *Direct Encapsulation:* Introducing AMPs during the hydration process so they integrate into the lipid bilayer or interfacial regions.
- *Post-Formation Loading:* For peptides sensitive to formulation conditions, incubate them with the pre-formed disks at room temperature under gentle stirring.

Purification of Nanodisks

- *Separation of Free AMPs:* Removing unencapsulated peptides using ultracentrifugation, ultrafiltration, or size-exclusion chromatography.
- *Concentration:* Concentrating the purified bilayer disks using dialysis or other concentration techniques for subsequent applications.

Characterization of Bilayer Disks

- *Size and Morphology:* Assessing particle size and shape using dynamic light scattering (DLS), transmission electron microscopy (TEM), or atomic force microscopy (AFM).
- *Encapsulation Efficiency (EE):* Quantifying AMP loading using UV-Vis spectroscopy, high-performance liquid chromatography (HPLC), or fluorescence assays.

- *Structural Validation:* Confirming bilayer structure using cryo-electron microscopy (cryo-EM) or small-angle X-ray scattering (SAXS).
- *Stability and Release:* Evaluating stability under physiological conditions and perform in vitro release studies to monitor AMP release rates using HPLC.

Optimization Considerations

- *Lipid-to-AMP Ratio:* Adjusting to enhance encapsulation while maintaining stability.
- *Stabilizer Type and Amount:* Optimizing edge stabilizers to minimize aggregation and fine-tune disk size.
- *Buffer Properties:* Testing different pH and ionic strengths to ensure structural integrity and AMP stability.
- *Lipid Composition:* Varying phospholipid types to modulate disk size and AMP interaction.

Applications of Bilayer Disks in AMP Delivery

- *Therapeutics:* Target delivery to combat antibiotic-resistant infections and biofilms.
- *Topical Treatments:* Formulations for wound care, especially in bacterial infections.
- *Systemic Administration:* Intravenous delivery for enhanced stability and reduced systemic toxicity.
- *Vaccine Development:* Delivery of immunomodulatory peptides to boost vaccine efficacy.

By optimizing the formulation and characterization processes, bilayer disks can become highly effective vehicles for AMPs, offering protection, precise delivery, and controlled release, paving the way for innovative treatments in antimicrobial therapy.

Development of Chewing Gum as a Delivery System for Antimicrobial Peptides (AMPs)

Chewing gum offers a novel and effective approach for delivering antimicrobial peptides (AMPs) directly to the oral cavity. It ensures prolonged release, enhancing local antimicrobial effects, making it an excellent option for oral hygiene, infection prevention, and treatment of localized oral conditions like periodontitis and halitosis. Chewing gums contain salivary-released antiplaque chemicals that help prevent dental plaque, which is brought on by bacterial-tooth interactions.

Core Ingredients

- *Gum Matrix:* Providing the chewy texture, using natural or synthetic elastomers, such as chicle, polyvinyl acetate, or styrene-butadiene rubber.
- *Plasticizers:* Enhancing flexibility and improve texture (e.g., glycerol, lanolin).
- *Softeners:* Maintaining chewability (e.g., lecithin, vegetable oils).
- *Antimicrobial Peptides:* Hydrophilic or amphiphilic peptides specifically formulated for antimicrobial action in the oral cavity.

Sweetening Agents

- *Bulk Sweeteners:* Adding sweetness and volume, such as sorbitol, xylitol, or maltitol.
- *Intense Sweeteners:* Providing heightened sweetness without bulk, including aspartame, sucralose, or stevia.
- *Flavor Enhancers:* Natural or artificial flavoring agents (e.g., mint, fruit, or herbal extracts) for better consumer appeal.
- *Binders:* Polyvinylpyrrolidone (PVP) or similar compounds for stabilizing AMPs within the gum matrix.
- *Optional Additives:* Polyols or sugar-based coatings for improved appearance and controlled release.
- *Preservatives:* Minimize microbial contamination, such as potassium sorbate.
- *Colorants:* Natural or synthetic dyes for aesthetic purposes.

Preparation of AMP Powder

- To dissolve the AMPs in a suitable solvent or buffer (e.g., phosphate-buffered saline, PBS) to ensure stability.
- To lyophilize or spray-dry the solution to create a fine, stable powder for easy incorporation into the gum.

Gum Base Processing

- *Melting:* To heat the gum base to 60–90°C until pliable, avoiding excessive temperatures to preserve ingredient integrity.
- *Softener Integration:* To incorporate plasticizers and softeners (e.g., glycerol) into the molten gum base for optimal texture.

Mixing and Incorporating Ingredients

- To blend the AMP powder, sweeteners, flavors, and binders into the melted gum base.
- To ensure even distribution by thorough mixing under controlled conditions to maintain AMP activity.

Molding and Cooling

- To shape the mixture into molds or roll it out to the desired thickness.
- To cool rapidly to solidify the gum structure.

Optional Coating

If a polished finish is required, apply a polyol or sugar coating and dry the gum to set the coating.

Packaging

To package the gum in moisture-proof wrappers or containers to preserve quality and extend shelf life.

Quality Assessment

- *AMP Stability:* To verify AMP integrity during processing using methods like HPLC or mass spectrometry.
- *Release Characteristics:* To conduct in vitro studies in simulated saliva to confirm sustained peptide release.
- *Texture and Usability:* To test chewability and texture using mechanical analysis to ensure consumer acceptability.
- *Antimicrobial Efficacy:* To assess the gum's antimicrobial activity against oral pathogens (e.g., *Streptococcus mutans*) through microbiological assays.
- *Sensory Evaluation:* To evaluate flavor, sweetness, and overall palatability via sensory testing.

Optimization Considerations

- *AMP Concentration:* To adjust peptide loading to balance efficacy and product stability.
- *Gum Base Composition:* To optimize elastomer, plasticizer, and softener ratios for improved texture and release behavior.
- Controlled Release: To modify binders or coatings to achieve a consistent and sustained release of AMPs in the oral cavity.
- Sweetener Selection: To use xylitol or similar sugar alcohols for additional oral health benefits, such as reducing dental caries.

Applications

- *Oral Hygiene:* To prevent dental caries, gum disease, and bad breath through targeted AMP delivery.

- P*ost-Dental Procedures:* To promote healing and reduce infection risk after oral surgeries or procedures.
- *Antimicrobial Treatments:* To provide localized treatment for oral infections and biofilm-related conditions.
- *General Oral Care:* To offer an easy-to-use, consumer-friendly format for regular antimicrobial protection.

Chewing gum containing AMPs is a practical and effective solution for delivering therapeutic agents directly to the oral cavity, enhancing user compliance and therapeutic outcomes.

Formulation of Phytoglycogen (PGG) Nanoparticles for Antimicrobial Peptide (AMP) Delivery

Phytoglycogen (PGG), a naturally occurring polysaccharide derived from sources like sweet corn, is a highly biocompatible and biodegradable material. Its branched structure and large surface area make it an excellent candidate for creating nanoparticles that can encapsulate and deliver antimicrobial peptides (AMPs). These nanoparticles protect AMPs, improve their bioavailability, and enable targeted therapeutic effects. Phytoglycogen (PGG) nanoparticles, a water-soluble α-d-glucan from plants, have been used to create novel nisin nanocarriers by subjecting them to β-amylolysis.

Core Material

Phytoglycogen (PGG): Serveing as the structural matrix with functional surface properties.

Active Agent

- *AMPs:* Antimicrobial peptides designed to combat microbial infections effectively.
- *Optional Crosslinkers:* Substances like glutaraldehyde, sodium tripolyphosphate (TPP), or carbodiimides to enhance nanoparticle stability.
- *Stabilizers/Surfactants:* Polymers, such as polyethylene glycol (PEG), polyvinyl alcohol (PVA), or surfactants like Tween 80 to improve stability and prevent aggregation.
- *Buffers:* Solutions like phosphate-buffered saline (PBS) or Tris buffer to maintain pH and AMP activity during nanoparticle preparation.
- *Optional Organic Solvents:* Ethanol or dimethyl sulfoxide (DMSO) to assist in dissolving specific ingredients.
- *Deionized Water:* Used for dissolving, washing, and purifying nanoparticles.

Preparing PGG Nanoparticles

- *Dissolution:* Dissolving PGG in deionized water or a buffer at concentrations between 5–10 mg/mL to form a homogeneous solution.
- *Nanoparticle Formation:* Antisolvent Precipitation: Gradually adding ethanol or acetone to the PGG solution while stirring to initiate nanoparticle assembly.
- *Ionic Gelation:* Introducing a crosslinking agent like TPP dropwise into the PGG solution to form nanoparticles, if needed.
- *Stabilization:* Adding surfactants (e.g., PEG or PVA) during nanoparticle formation to stabilize the particles and prevent clumping.

Loading AMPs into PGG Nanoparticles

- *Passive Encapsulation:* Mixing AMPs with the PGG solution before forming nanoparticles. During assembly, peptides are encapsulated into the nanoparticles.
- *Surface Adsorption:* Post-formation, incubate the nanoparticles with an AMP solution to allow peptides to bind to the surface.
- *Electrostatic Interaction:* Adjusting the pH of the PGG solution to create a charge opposite to the AMPs, promoting their binding through electrostatic attraction.

Purification

- *Washing:* Removing unbound peptides and impurities by centrifugation, followed by resuspension in fresh buffer.
- *Dialysis:* Using a dialysis membrane to further purify the nanoparticles by separating them from smaller contaminants.
- *Filtration:* Filtering the final suspension through a sterile 0.22 μm membrane for sterilization.

Characterization of Nanoparticles

Particle Size and Charge

Analyzing size, polydispersity index (PDI), and zeta potential using techniques like dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA).

Encapsulation Efficiency (EE)

Measuring AMP loading using methods like UV-Vis spectroscopy, high-performance liquid chromatography (HPLC), or fluorescence assays.

- *Morphological Assessment:* Examining the shape and structure of nanoparticles using transmission electron microscopy (TEM) or scanning electron microscopy (SEM).
- *Release Profile:* Conducting in vitro release studies in a simulated physiological medium (e.g., PBS at 37°C) to assess the sustained release of AMPs.
- *Stability Testing:* Evaluating particle stability under various storage conditions and biological environments.

Optimization Parameters

- *PGG Concentration:* Adjusting to control particle size and maximize AMP encapsulation.
- *AMP-to-PGG Ratio:* Balancing peptide loading with nanoparticle integrity to optimize therapeutic efficacy.
- *Crosslinker Use:* Varying the type and amount of crosslinker to fine-tune nanoparticle rigidity and AMP release behavior.
- *Surfactant Concentration:* Optimizing to maintaining particle stability and prevent aggregation without interfering with peptide activity.
- *Buffer pH and Ionic Strength:* Tailor buffer conditions to ensure AMP stability and enhance encapsulation efficiency.

Applications

- *Therapeutics:* Delivering AMPs to combat bacterial infections, particularly in biofilm-related conditions.
- *Topical Use:* Incorporating PGG nanoparticles into gels or creams for treating skin infections and enhancing wound healing.
- *Oral Delivery:* Protecting AMPs against degradation in the gastrointestinal tract for improved bioavailability.
- *Diagnostic Tools:* Using AMP-loaded nanoparticles labeled with fluorescent tags for microbial detection and imaging.
- *Vaccines:* Co-delivering AMPs with immunostimulatory agents to enhance immune responses.

Phytoglycogen nanoparticles offer an advanced delivery system for AMPs, effectively combining natural biocompatibility with customizable nanocarrier properties. These features enable their application across a range of therapeutic and diagnostic fields, ensuring enhanced peptide stability, sustained release, and targeted antimicrobial activity.

Developing Hydrogels for Antimicrobial peptides (AMPs)

Developing hydrogels for antimicrobial peptides (AMPs) focuses on creating systems capable of encapsulating, stabilizing, and releasing AMPs in a controlled manner, ensuring their antimicrobial effectiveness. Below is an overview of the formulation process:

Key Factors to Consider

- *AMP Protection:* Shielding AMPs from enzymatic breakdown, extreme pH, and temperature fluctuations.
- *Release Dynamics:* Designing systems for sustained or stimuli-triggered release to optimize antimicrobial action.
- *Biocompatibility:* Employing safe, non-toxic materials, especially for use in medical applications.
- *Hydrogel Properties:* Customizing mechanical strength and porosity to suit specific applications, such as wound care or drug delivery.

Hydrogel Components

Polymers

- *Natural:* Examples include gelatin, alginate, hyaluronic acid, chitosan, and collagen.
- *Synthetic:* Materials like poly (ethylene glycol) (PEG), poly (vinyl alcohol) (PVA), and polypeptides.

Crosslinking Agents

- *Physical:* Methods, such as ionic interactions (e.g., calcium ions with alginate) and hydrogen bonding.
- *Chemical:* Covalent crosslinking using compounds like glutaraldehyde, genipin, or carbodiimides.
- *Photo-Induced:* Using light and photoinitiators like Irgacure.
- *AMP Incorporation:* During gelation, AMPs are embedded before crosslinking.

Alternatively, they can be introduced post-gelation via diffusion.

Additives

- *Nanoparticles:* Silver or silica particles to enhance structure or antimicrobial activity.
- *Stabilizers:* Compounds like trehalose to preserve AMP functionality.
- *Encapsulation of AMPs:* Embedding AMPs within the hydrogel matrix to protect them from environmental factors.
- *Covalent Bonding:* Attaching AMPs to hydrogel polymers for enhanced stability, allowing controlled release through enzymatic or hydrolytic mechanisms.

Stimuli-Responsive Systems

- *Hydrogels Sensitive to Environmental Triggers:* pH changes (acidic conditions at infection sites). Temperature shifts (activation at body temperature).
- Light (external activation for on-demand release).

Hydrogel Fabrication Approaches

- *Injectable Systems:* In-situ gelation triggered by temperature, light, or pH for minimally invasive applications.
- *3D Printing:* High precision fabrication of hydrogel structures, ideal for wound dressings or scaffolds.
- *Layered Construction:* To assemble multiple layers for tailored AMP release profiles.

Characterization of Hydrogel Systems

- *Assessing AMP Activity:* To test antimicrobial efficacy via methods like minimum inhibitory concentration (MIC) assays.
- *Physical Properties:* To measure mechanical strength (using rheology) and evaluate swelling and porosity for controlled release.
- *Release Profiles:* To monitor AMP release over time with in vitro assays.
- *Safety Testing:* To conduct cytotoxicity studies on mammalian cells and hemocompatibility tests for injectable applications.

Applications of AMP Hydrogels

- *Wound Care:* Hydrogels serve as antimicrobial dressings to protect against infections and aid in healing.
- *Targeted Drug Delivery:* To ensure localized AMP delivery to infection sites.
- *Tissue Engineering:* To prevent microbial contamination in tissue scaffolds.
- *Example:* Chitosan-Based AMP Hydrogel
- To prepare a 1% acetic acid solution to dissolve chitosan.
- To mix the AMP solution with chitosan at the desired concentration.
- To crosslink using genipin or β-glycerophosphate under gentle stirring.
- To pour the mixture into a mold or apply it directly for in-situ gelation.
- This method effectively encapsulates AMPs, protecting them while enabling sustained delivery.

Bacteriophages

The project aimed to create a bacteriophage platform that could efficiently destroy bacterial cells. Researchers selected Ponericin W3 and W5 due to their low minimum inhibitory concentrations (MICs), minimal bacterial regrowth, and potent bactericidal activity. They combined an OmpA-derived signal peptide to target the translated precursor for secretion and created M13mp18 phages to overexpress these phages. The phages showed a 10,000-fold increase in bacterial death, indicating a potent and sustained bactericidal impact. This strategy could increase the efficacy of antimicrobial tactics in industrial, agricultural, and food processing contexts.

Bacteria are infected and multiply by bacteriophages, which recognize and attach to bacterial membranes. However, the development of bacteriophages was halted by the discovery of cheap antibiotics in the 1950s. Modern molecular biology has made it possible to re-engineer bacteria and express foreign proteins to address concerns and confer new functionality. By overexpressing broad-spectrum lytic drugs during infection, this work increases bacterial death and tackles bacterial resistance to phages.

The Biopolymers Lab at the Massachusetts Institute of Technology used Fmoc chemistry to create antimicrobial peptides for the study. They tested the peptides for bactericidality using a Minimum Inhibitory Concentration (MIC) and an optical density (OD600). The modified phage expressing Ponericin W3 demonstrated a 10,000-fold increase in bacterial death, demonstrating a potent and long-lasting bactericidal action.

Preparation of Bacteriophages

Preparing bacteriophages requires a systematic approach to isolate, amplify, purify, and evaluate their activity against a specific bacterial target.

Isolation of Bacteriophages

Required Materials

- Environmental samples (e.g., sewage, soil, or water).
- Target bacterial strain (e.g., *Escherichia coli*).
- Culture medium, such as Luria-Bertani (LB) broth or agar.

Procedure

- *Collecting Samples:* Gather environmental samples likely to contain phages specific to *E. coli*.
- *Enriching the Sample:* Combine the sample with LB broth containing the target *E. coli* strain. Incubate overnight at 37°C to encourage phage multiplication.
- *Centrifuge:* Spinning the enriched culture at 10,000 × g for 10 minutes to remove solid debris and bacterial cells.
- *Filter:* Passing the supernatant through a 0.22 μm filter to remove remaining bacteria, leaving behind the phages.

Propagation of Bacteriophages

Required Materials

- Filtered phage-containing solution.
- Fresh *E. coli* culture.
- LB broth and agar.
- *Preparing Host Bacteria*: Grow *E. coli* until it reaches the exponential growth phase (OD600 ~ 0.4–0.6).
- *Infecting the Host:* Mix the phage solution with the bacterial culture and incubate at 37°C under shaking conditions for 4–6 hours.
- *Observing Lysis:* Look for signs of bacterial lysis, such as clearing of the culture.
- *Harvesting Phages:* Centrifuging and filtering the lysate to separate phages from residual bacteria.

Purification of Bacteriophages

Purification Methods

- *Centrifugation:* Removing any remaining debris by centrifuging at 10,000 × g for 10 minutes.
- *Precipitation:* Adding 10% (w/v) polyethylene glycol (PEG-8000) and 1 M sodium chloride (NaCl) to the lysate.
- Incubating the mixture at 4°C for 4–12 hours.
- Centrifuging at 10,000 × g for 15 minutes and collect the pellet containing phages.
- Resuspending the phage pellet in a minimal amount of SM buffer (50 mM Tris-HCl, 100 mM NaCl, 8 mM $MgSO_4$, pH 7.5).
- *Cesium Chloride Gradient:* Using ultracentrifugation with a CsCl gradient to separate phages based on their density.
- *Dialysis:* Dialyzing the purified phages in SM buffer to remove residual salts and chemicals.

Characterization of Bacteriophages

- *Titer Determination:* Performing plaque assays to calculate phage concentration in plaque-forming units per milliliter (PFU/mL).
- Combining serial dilutions of the phage solution with *E. coli*, plate the mixture on LB agar, and incubate overnight at 37°C. Count the plaques formed.
- *Host Range Testing:* Assessing the phage's ability to infect various *E. coli* strains to determine its specificity.
- *Stability Evaluation:* Testing the phage's stability under different pH levels, temperatures, and storage conditions.

Storage of Bacteriophages

- *Short-Term Storage:* Keeping phage preparations at 4°C in SM buffer for several months.
- *Long-Term Storage:* Adding 10% glycerol as a cryoprotectant and store at -80°C.
- Alternatively, freeze-dry (lyophilize) the phages for extended shelf life.

Outcome

This procedure yields high-purity, biologically active phages ready for use in applications like phage therapy, bacterial biocontrol, and scientific research.

Formulating bacteriophages targeting *Escherichia coli* involves creating delivery systems that preserve phage stability, enhance effectiveness, and enable controlled release to combat infections efficiently. Below is a revised, plagiarism-free guide.

Essential Considerations in Phage Formulation

- *Stability:* Phages are susceptible to environmental factors, such as heat, pH fluctuations, and enzymatic breakdown.

- *Specificity:* Selecting phages that specifically target *E. coli* strains to avoid disruption of beneficial microbiota.
- *Controlled Release:* Using delivery systems that allow gradual or site-specific release to prolong phage action.
- *Compatibility:* Ensuring formulation components do not interfere with the phages' ability to infect and lyse bacteria.

Components for Phage Delivery Systems

Stabilizers

- *Sugars:* Trehalose, sucrose, or glucose to enhance stability during storage.
- *Proteins:* Protective agents like bovine serum albumin (BSA).
- *Polymers:* Polyethylene glycol (PEG) to improve phage stability.

Encapsulation Materials

- *Natural Polymers:* Alginate, chitosan, or gelatin for biocompatibility.
- *Synthetic Polymers:* Poly (lactic-co-glycolic acid) (PLGA) for sustained release.

Additives

- *Buffers:* Phosphate-buffered saline (PBS) or Tris-HCl to maintain optimal pH.
- *Antimicrobials:* Optional inclusion of antibiotics for synergistic action against resistant bacteria.

Strategies for Phage Formulation

Encapsulation Methods

- *Microencapsulation:* Incorporating phages into microspheres made from alginate or PLGA for localized delivery.
- *Hydrogels:* Embedding phages within hydrogels for use in wound care or localized infections; crosslinked with agents like calcium ions for structural stability.
- *Liposomes:* Encasing phages in lipid vesicles to protect them during transit and enhance mucosal delivery.

Powder Formulations

- *Spray Drying:* Creating phage powders stabilized with trehalose or similar excipients for reconstitution when needed.
- *Freeze-Drying (Lyophilization):* Preserving phages for long-term storage using protectants like sucrose or trehalose to prevent activity loss during the drying process.

Smart Delivery Systems

pH-Responsive Coatings: Developing materials that release phages in response to specific pH levels, such as acidic or neutral conditions in the gastrointestinal tract.

Evaluation of Phage Formulations

- *Viability Testing:* Quantifying active phages by measuring plaque-forming units (PFU/mL) after formulation.
- *Release Profiles:* Studying release kinetics in simulated environments to ensure phage availability at the target site.
- *Stability:* Evaluating how well the formulation maintains phage activity under different temperatures, pH levels, and light exposure.
- *Efficacy:* Testing the effectiveness of the formulation against *E. coli* strains in laboratory and animal studies.
- *Safety Assessment:* Performing toxicity tests on host cells or animal models to ensure safety.

Applications of Formulated Phages

- *Medical Use:* Treating *E. coli*-related infections, including urinary tract infections (UTIs), gastrointestinal disorders, or wound infections.
- *Food Safety:* Decontaminating fresh produce, meat, or food-processing surfaces to reduce *E. coli* contamination.
- *Agricultural Use:* Using phages to control *E. coli* in livestock, minimizing zoonotic transmission risks.
- *Example:* Alginate-Based Phage Encapsulation
- *Phage Preparation:* Isolating and purifying phages specific to *E. coli*.
- *Preparing Alginate Solution:* Dissolve 2–3% (w/v) sodium alginate in sterile water.

Encapsulation Process

- Mixing the phage solution with the alginate.
- Dropping the mixture into a 0.1–0.2 M calcium chloride solution to form gel beads.
- *Drying:* Air-dry or lyophilize the beads for storage.
- *Application:* Rehydrate the beads before use or apply them directly to the infection site for controlled release [8–10].

RESULTS AND DISCUSSION

Antimicrobial Peptides (AMPs) and Bacteriophages as Alternatives to Conventional Antibiotics.

The exploration of antimicrobial peptides (AMPs) and bacteriophages as alternatives to traditional antibiotics has revealed encouraging outcomes. These agents demonstrate distinct mechanisms of action, reduced risk of resistance development, and strong potential for combating multidrug-resistant (MDR) bacteria.

Antimicrobial Peptides (AMPs)

Broad-Spectrum Antimicrobial Activity: AMPs showed efficacy against both Gram-positive and Gram-negative bacteria, including MDR strains, such as *Escherichia coli*, *Staphylococcus aureus*, and

Pseudomonas aeruginosa

- *Mechanism of Action:* The peptides primarily disrupt bacterial membranes via electrostatic interactions, leading to rapid bacterial cell lysis without requiring internalization.
- *Synergistic Effects:* When used in combination with antibiotics, AMPs enhanced overall antimicrobial effectiveness, lowering the required antibiotic dosages and potentially reducing resistance development.
- *Safety and Selectivity:* Cytotoxicity tests indicated that most AMPs selectively targeted bacterial cells while exhibiting minimal effects on mammalian cells at therapeutic levels.

Bacteriophages

- *Host-Specific Targeting:* Phages effectively eliminated specific bacterial strains without disrupting beneficial microbiota, addressing a key limitation of traditional antibiotics.
- *Activity Against MDR Pathogens:* Phages were successful in lysing resistant bacteria, including carbapenem-resistant *E. coli* and methicillin-resistant *Staphylococcus aureus* (MRSA).
- *Formulation Stability:* Encapsulation methods, such as alginate bead systems, preserved phage viability under various storage and environmental conditions, supporting their usability in medical applications.
- *Synergistic Use with Antibiotics:* Phages combined with antibiotics enhanced bacterial eradication and minimized the emergence of resistant strains.

Advantages Over Conventional Antibiotics

- *Lower Resistance Potential:* AMPs target essential bacterial structures, such as membranes, making resistance development less likely. Bacteriophages evolve in response to bacterial defenses, maintaining their effectiveness over time.

- *Precision Targeting:* Phages uniquely target specific bacteria, leaving beneficial microbiota unharmed, unlike broad-spectrum antibiotics.
- *Broad Utility:* AMPs can also target fungi and viruses, broadening their applications beyond bacterial infections.

Challenges and Limitations for AMPs

- *Stability Issues:* Susceptibility to enzymatic degradation may limit their activity and shelf life. Formulation techniques, such as encapsulation, are needed to improve stability.
- *High Production Costs:* Synthetic AMP production remains costly compared to conventional antibiotics, impacting scalability.

For Bacteriophages

- *Narrow Host Range:* Phages are highly specific, necessitating precise bacterial identification for effective use. This limits their applicability without advanced diagnostics.
- *Regulatory Complexity:* The use of live biological agents like phages poses challenges in standardizing formulations and gaining regulatory approvals.

Synergistic Applications

- *AMP-Phage Combinations:* AMPs can disrupt bacterial membranes, facilitating phage entry into bacterial cells. This dual approach could enhance efficacy while reducing the likelihood of resistance.
- *Advanced Delivery Systems:* Incorporating AMPs and phages into responsive hydrogels or nanoparticles ensures stability and targeted release, particularly for localized infections, such as wounds or intestinal diseases.

Future Directions

- *Improved Formulations:* Efforts should focus on developing cost-effective, stable formulations for both AMPs and phages.
- *Personalized Antimicrobials:* Tailoring AMP and phage therapies to individual infections through advancements in molecular diagnostics and phage engineering.
- *Clear Regulatory Pathways:* Establishing comprehensive regulatory frameworks will facilitate the clinical use of these novel antimicrobials.

CONCLUSIONS

Antimicrobial peptides and bacteriophages offer promising, innovative solutions to the growing challenge of antibiotic resistance. Although obstacles like stability, production cost, and regulatory hurdles persist, their unique mechanisms and potential for integration into advanced therapies highlight their transformative role in future antimicrobial treatments. Combining these agents with smart delivery systems and traditional antibiotics could revolutionize the management of MDR infections.

Acknowledgment

This research work is acknowledged to STM Journal and Bengal College of Pharmaceutical Technology, Dubrajpur, West Bengal.

REFERENCES

1. Lemon DJ, Kay MK, Titus JK, Ford AA, Chen W, Hamlin NJ, et al. Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018. J Microbiol. 2019 Jun;57(6):532–8.
2. Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: A patent review (2003–2015). Expert Opin Ther Pat. 2016 Jun 2;26(6):689–702.
3. Mandal SM, Roy A, Ghosh AK, Hazra TK, Basak A, Franco OL. Challenges and future prospects of antibiotic therapy: From peptides to phages utilization. Front Pharmacol. 2014 May 13;5:105.

4. Lopes BS, Hanafiah A, Nachimuthu R, Muthupandian S, Md Nesran ZN, Patil S. The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance. Molecules. 2022 May 6;27(9):2995.
5. Lopes BS, Hanafiah A, Nachimuthu R, Muthupandian S, Md Nesran ZN, Patil S. The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance. Molecules. 2022 May 6;27(9):2995.
6. León-Buitimea A, Garza-Cárdenas CR, Garza-Cervantes JA, Lerma-Escalera JA, Morones-Ramírez JR. The demand for new antibiotics: antimicrobial peptides, nanoparticles, and combinatorial therapies as future strategies in antibacterial agent design. Front Microbiol. 2020 Jul 24;11:1669.
7. Alaoui Mdarhri H, Benmessaoud R, Yacoubi H, Seffar L, Guennouni Assimi H, Hamam M, et al. Alternatives therapeutic approaches to conventional antibiotics: Advantages, limitations and potential application in medicine. Antibiotics. 2022 Dec 16;11(12):1826.
8. Chau T. Delivery, design, and mechanism of antimicrobial peptides. [dissertation]. Massachusetts Institute of Technology; 2014.
9. Carmona-Ribeiro AM, Carrasco LD. Novel formulations for antimicrobial peptides. Int J Mol Sci. 2014 Oct 9;15(10):18040–83.
10. Brandelli A. Nanostructures as promising tools for delivery of antimicrobial peptides. Mini Rev Med Chem. 2012 Jul 1;12(8):731–41.

